Author: claimsbot

1. A pharmaceutical composition in the form of a solid carrier comprising an admixture of: (a) a pharmaceutical active ingredient selected from the group consisting of: analgesics, anti-inflammatory agents, antihelminthics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxiolytic agents, sedatives, hypnotics, neuroleptics, \u03b2-blockers, cardiac inotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastro-intestinal agents, histamine receptor antagonists, keratolyptics, lipid regulating agents, anti-anginal agents, Cox-2 inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, nutritional agents, opiod analgesics, protease inhibitors, sex hormones, stimulants, muscle relaxants, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof, (b) an effective solubilizing amount of at least one hydrophiliac surfactant, which is effective to partially or fully solubilize the pharmaceutically active ingredient in the solid carrier, and optionally (c) an additive, wherein the at least one hydrophilic surfactant is selected from: (i) a hydrophilic surfactant that solidifies at ambient room temperature; (ii) a mixture of hydrophilic surfactants that in combination solidify at ambient room temperature; (iii) a hydrophilic surfactant that solidifies at ambient room temperature in the presence of the additive; and (iv) a combination of two or more of (i), (ii), and (iii), wherein the effective solubilizing amount of the at least one hydrophilic surfactant is an amount effective to facilitate sustained solubilization of the active ingredient upon administration, with the proviso that when the at least one hydrophilic surfactant includes (iii), the composition then includes the optional additive.
2. A pharmaceutical composition in the form of a solid carrier comprising an admixture of: (a) a pharmaceutical active ingredient; (b) an effective solubilizing amount of at least one hydrophilic surfactant selected from the group consisting of (i) polyoxyethylene sorbitan fatty acid esters, (ii) polyoxyethylene-polyoxypropylene block copolymers, (iii) polyglycerol fatty acid esters, (iv) polyoxyethylene glycerides, (v) polyoxyehtylene sterols, deriviatives, and analogues thereof, (vi) polyoxyehtylene vegetable oils, (vii) polyoxyethylene hydrogenated vegetable oils, (viii) reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols (ix) tocopheryl polyethylene glycol succinates, (x) sugar esters, (xi) sugar ethers, (xii) sucroglycerides, and (xiii) mixtures thereof; and (c) an additive to provide for controlled release of the active ingredient following administration to a patient, said additive selected from the group consisting of polyvinylpyrrolidone, polyethylene glycol, hydroxypropyl methylcellulose, hyrosypropyl cellulose and other cellulose derivatives and mixtures thereof.
3. The pharmaceutical composition of claim 1, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to facilitate rapid dispersion of the active ingredient upon administration.
4. The pharmaceutical composition of claim 3, wherein the rapid dispersion comprises micellization andor emulsification.
5. The pharmaceutical composition of claim 1, wherein the carrier further comprises a substrate and wherein the admixture is in the form of an encapsulation coat on the substrate.
6. The pharmaceutical composition of claim 5, wherein the substrate is a powder or a multiparticulate.
7. The pharmaceutical composition of claim 6, wherein the substrate is a multiparticulate selected from the group consisting of granules, pellets, beads, spherules, beadlets, microcapsules, millispheres, nonocapsules, microspheres, platelets, tablets, and capsules.
8. The pharmaceutical composition of claim 1, wherein the composition includes the additive.
9. The pharmaceutical composition of claim 8, wherein the additive is selected from the group consisting of solubilizers, enzyme inhibitors, anti-adherents, anticoagulants, antifoaming agents, antioxidants, binders, bufferants, chelating agents, coagulants, colorants, opaquants, coolants, cryoprotectants, diluents, fillers, disintegrants, super disintegrants, hydrogen bonding agents, flavorants, desensitizers, ion-exchange resins, plasticizers, preservatives, solvents, sweeteners, thickeners, and mixtures thereof.
10. The pharmaceutical composition of claim 9, wherein the additive is selected from the group consisting of anti-adherents, binders, and disintegrants.
11. The pharmaceutical composition of claim 10, wherein the additive is an anti-adherent selected from the group consisting of talc, magnesium stearate, fumed silica, micronized silica, polyethylene glycols, surfactants, waxes, stearic acid, stearic acid salts, stearic acid derivatives, starch, hydrogenated vegetable oils, sodium benzoate, sodium acetate, leucine, PEG-4000 and magnesium lauryl sulfate.
12. The pharmaceutical composition of claim 10, wherein the additive is a binder selected from the group consisting of matrix binders, film binders, and chemical binders.
13. The pharmaceutical composition of claim 10, wherein the additive is a disintegrant selected from the group consisting of croscarmellose sodium, starch, starch derivatives, clays, gums, cellulose, cellulose derivates, alginates, crosslinked polyvinylpyrrolidone, sodium starch glycolate and microcrystalline cellulose.
14. The pharmaceutical composition of claim 8, wherein the additive is polyvinylpyrrolidone.
15. The pharmaceutical composition of claim 8, wherein the additive is cyclodextrin.
16. The pharmaceutical composition of claim 8, wherein the additive is polyethylene glycol.
17. The pharmaceutical composition of claim 16, wherein the additive is a cellulosic polymer.
18. The pharmaceutical composition of claim 17, wherein the cellulosic polymer is selected from the group consisting of sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropylmethyl cellulose.
19. The pharmaceutical composition of claim 18, wherein the cellulosic polymer is hydroxypropylmethyl cellulose.
20. The pharmaceutical composition of claim 1, wherein the active ingredient is a drug, a nutrient, a cosmeceutical, a diagnostic agent, a salt thereof, an isomer thereof, a derivative thereof, or a mixture thereof.
21. The pharmaceutical composition of claim 1, wherein the active ingredient has an intrinsic aqueous solubility of less than about 1 mgmL.
22. A pharmaceutical composition in the form of a solid carrier comprising a substrate and an encapsulation coat on the substrate, wherein the encapsulation coat comprises a therapeutically effective amount of a hydrophobic pharmaceutical active ingredient and an effective solubilizing amount of at least one hydrophilic surfactant, wherein the effective solubilizing amount of the at least one hydrophilic surfactant is an amount effective to facilitate sustained solubilization of the active ingredient upon administration.
23. The pharmaceutical composition of claim 1, wherein the active ingredient is selected from the group consisting of analgesics, anti-bacterial agents, anti-viral agents, anti-inflammatory agents, anti-depressants, anti-diabetics, anti-epileptics, anti-hypertensive agents, anti-migraine agents, immunosuppressants, anxiolytic agents, sedatives, hypnotics, neuroleptics, \u03b2-blockers, gastro-intestinal agents, lipid regulating agents, anti-anginal agents, Cox-2 inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, opioid analgesics, protease inhibitors, sex hormones, cognition enhancers, anti-urinary incontinence agents, and mixtures thereof.
24. The pharmaceutical composition of claim 1, wherein the active ingredient is selected from the group consisting of acetretin, albendazole, albuterol, aminoglutethimide, amiodarone, amlodipine, amphetamine, amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen, beclomethasone, benezepril, benzonatate, betamethasone, bicalutanide, budesonide, bupropion, busulfan, butenafine, calcifediol, calcipotriene, calcitriol, camptothecin, candesartan, capsaicin, carbamezepine, carotenes, celecoxib, cerivastatin, cetirizine, chlorpheniramine, cholecalciferol, cilostazol, cimetidine, cinnarizine, ciprofloxacin, cisapride, clarithromycin, clemastine, clomiphene, clomipramine, clopidogrel, codeine, coenzyme Q10, cyclobenzaprine, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, dicoumarol, digoxin, dehydroepiandrosterone, dihydroergotamine, dihydrotachysterol, dirithromycin, donezepil, efavirenz, eprosartan, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, glipizide, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, lisinopril, loperamide, loratadine, lovastatin, L-thryroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, nifedipine, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, oestradiol, oxaprozin, paclitaxel, paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudoephedrine, pyridostigmine, rabeprazole, raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sertraline, sibutramine, sildenafil citrate, simvastatin, sirolimus, spironolactone, sumatriptan, tacrine, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, telmisartan, teniposide, terbinafine, terazosin, tetrahydrocannabinol, tiagabine, ticlopidine, tirofibran, tizanidine, topiramate, topotecan, toremitfene, tramadol, tretinoin, troglitazone, trovafloxacin, ubidecarenone, valsartan, venlafaxine, verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, zolpidem, zopiclone, pharmaceutically acceptable salts, isomers, and derivatives thereof, and mixtures thereof.
25. The pharmaceutical composition of claim 24, wherein the active ingredient is selected from the group consisting of acetretin, albendazole, albuterol, aminoglutethimide, amiodarone, amlodipine, amphetamine, amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen, benzonatate, bicalutanide, busulfan, butenafine, calcifediol, calcipotriene, calcitriol, camptothecin, capsaicin, carbamezepine, carotenes, celecoxib, cerivastatin, chlorpheniramine, cholecaliferol, cimetidine, cinnarizine, ciprofloxacin, cisapride, cetirizine, clarithromycin, clemastine, clomiphene, codeine, coenzyme Q10, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, digoxin, dehydrepiandrosterone, dihydroergotamine, dihyrotachysterol, dirithromycin, donepezil, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, glipizide, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, lovastatin, L-thryroxine, lutein, lycopene, mifepristone, mefloquine, megestrol acetate, methdone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, medroxyprogesterone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol, oxaprozin, paclitaxel, paracalcitol, pentazocine, pioglitazone, pizofetin, pravastatin, probucol, progesterone, pseudoephedrine, pyridostigmine, rabeprazole, raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sibutramine, sildenafil citrate, simvastatin, sirolimus, spironolactone, sumatriptan, tacrine, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, teniposide, terbinafine, tetrahydrocannabinol, tiagabine, tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin, troglitazone, trovafloxacin, verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, zolpidem, zopiclone, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
26. The pharmaceutical composition of claim 25, wherein the active ingredient is selected from the group consisting of acetretin, albuterol, aminoglutethimide, amiodarone, amlodipine, amprenavir, atorvastatin, atovaquone, baclofen, benzonatate, bicalutanide, busulfan, calcifediol, calcipotriene, calcitriol, camptothecin, capsaicin, carbamezepine, carotenes, celecoxib, chlorpheniramine, cholecaliferol, cimetidine, cinnarizine, cisapride, citrizine, clemastine, coenzyme Q10, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, dehydroepiandrosterone, dihydroergotamine, dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, fluconazole, flurbiprofen, fosphenytoin, frovatriptan, furzolidone, glibenclamide, glipizide, glyburide, glymepride, ibuprofen, irinotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, lovastatin, L-thryroxine, lutein, lycopene, medroxyprogesterone, mifepristone, megestrol acetate, methoxsalen, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol, oxaprozin, paclitaxel, paracalcitol, pioglitazone, pizofetin, pranlukast, probucol, progesterone, pseudoephedrine, rabeprazole, raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sildenafil citrate, simvastatin, sirolimus, tramadol, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, teniposide, terbenafine, tetrahydrocannabinol, tiagabine, tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin, troglitazone, trovafloxacin, ubidecarenone, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, pharmaceutically acceptable salts, isomers and derivative thereof, and mixtures thereof.
27. The pharmaceutical composition of claim 26, wherein the active ingredient is selected from the group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporin, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lansoprazole, loratadine, lovastatin, megestrol acetate, montelukast, nabumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paracalcitol, pioglitazone, pranlukast, progesterone, pseudoephedrine, rabeprazole, rapamycin, rofecoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, saquinavir, sildenafil citrate, simvastatin, sirolimus, tramadol, tacrolimus, tamsulosin, teniposide, terbenafine, tetrahydrocannabinol, tiagabine, tizanidine, tramadol, troglitazone, vitamin A, vitamin D, vitamin E, zafirlukast, zileuton, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
28. The pharmaceutical composition of claim 1, wherein the active ingredient is selected from the group consisting of progesterone, dehydroepiandrosterone, amiodarone, spironolactone and mixtures thereof.
29. The pharmaceutical composition of claim 1, wherein the active ingredient is selected from the group consisting of clopidogrel, pioglitazone, zafirlukast, sertraline, tramadol, and fentanyl.
30. The pharmaceutical composition of claim 1, wherein the active ingredient is selected from the group consisting of tacrolimus, sirolimus, cilostazol, bicalutaminde, simvastatin, and lovastatin.
31. The pharmaceutical composition of claim 1, wherein the at least one hydrophilic surfactant comprises a non-ionic hydrophilic surfactant.
32. The pharmaceutical composition of claim 31, wherein the non-ionic hydrophilic surfactant has an HLB value of at least about 10.
33. The pharmaceutical composition of claim 31, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of alkylglucosides; alkylmaltosides; alkylthioglucosides; lauryl macrogolglycerides; polyoxyethylene alkyl ethers; polyoxyethylene alkylphenols; polyethylene glycol fatty acids esters; polyethylene glycol glycerol fatty acid esters; polyoxyethylene sorbitan fatty acid esters; polyoxyethylene-polyoxypropylene block copolymers; polyglycerol fatty acid esters; polyoxyethylene glycerides; polyoxyethylene sterols, derivatives, and analogues thereof; polyoxyethylene vegetable oils; polyoxyethylene hydrogenated vegetable oils; reaction mixtures of polyols and at least one member of the group consisting of fatty acids, glycerides, vegetable oils, hydrogenated vegetable oils, and sterols; tocopheryl polyethylene glycol succinates; sugar esters; sugar ethers; sucroglycerides; and mixtures thereof.
34. The pharmaceutical composition of claim 33, wherein the non-ionic hydrophilic surfactant is a polyoxyethylene sorbitan fatty acid esters.
35. The pharmaceutical composition of claim 34, wherein the polyoxyethylene sorbitan fatty acid ester is PEG-20 sorbitan monooleate.
36. The pharmaceutical composition of claim 33, wherein the non-ionic hydrophilic surfactant is a polyoxyethylene vegetable oil.
37. The pharmaceutical composition of claim 36, wherein the polyoxyethylene vegetable oil is polyethoxylated caster oil.
38. The pharmaceutical composition of claim 37, wherein the polyethoxylated caster oil is PEG-35 caster oil.
39. The pharmaceutical composition of claim 33, wherein the non-ionic hydrophilic surfactant is a polyoxyethylene hydrogenated vegetable oil.
40. The pharmaceutical composition of claim 39, wherein the polyoxyethylene hydrogenated vegetable oil is polyethoxylated hydrogenated caster oil.
41. The pharmaceutical composition of claim 40, wherein the polyethoxylated hydrogenated caster oil is PEG-40 hydrogenated castor oil.
42. The pharmaceutical composition of claim 33, wherein the non-ionic hydrophilic surfactant is a tocopheryl polyethylene glycol succinate.
43. The pharmaceutical composition of claim 42, wherein the tocopheryl polyethylene glycol succinate is tocopheryl PEG-1000 succinate.
44. The pharmaceutical composition of claim 33, wherein the non-ionic hydrophilic surfactant is a polyoxyethylene glyceride.
45. The pharmaceutical composition of claim 44, wherein the polyoxyethylene glyceride is a PEG-8 capryliccapric glyceride.
46. The pharmaceutical composition of claim 31, wherein the non-ionic hydrophilic surfactant is selected from the group consisting of lauryl macrogol glycerides and stearoyl macrogol glycerides.
47. The pharmaceutical composition of claim 46, wherein the non-ionic hydrophilic surfactant is a lauryl macrogol glyceride.
48. The pharmaceutical composition of claim 47, wherein the lauryl macrogol glyceride is lauryl macrogol-32 glyceride.
49. The pharmaceutical composition of claim 46, wherein the non-ionic hydrophilic surfactant is a stearoyl macrogol glyceride.
50. The pharmaceutical composition of claim 1, wherein the at least one hydrophilic surfactant comprises an ionic surfactant.
51. The pharmaceutical composition of claim 50, wherein the ionic surfactant is selected from the group consisting of alkyl ammonium salts; bile acids and salts, analogues, and derivatives thereof; fatty acid derivatives of amino acids, camitines, oligopeptides, and polypeptides; glyceride derivatives of amino acids, oligopeptides, and polypeptides; acyl lactylates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated monoglycerides; citric acid esters of mono- and di-glycerides; alginate salts; propylene glycol alginate; lecithins and hydrogenated lecithins; lysolecithin and hydrogenated lysolecithins, lysophospholipids and derivatives thereof; phospholipids and derivatives thereof; salts of alkylsulfates; salts of fatty acids; sodium docusate; and mixtures thereof.
52. The pharmaceutical composition of claim 1, wherein the solid carrier comprises a bead, a beadlet, a granule, a spherule, a pellet, a microcapsule, a microsphere, a nanosphere, a film, a wafer, a sprinkle, an implant, a troche, a lozenge, a platelet, a nanocapsule or a strip.
53. The pharmaceutical composition of claim 1, wherein the solid carrier is enteric coated, coated for fast disintegration, seal coated, film coated, barrier coated, compress coated, or coated with an enzyme-degradable coating.
54. The pharmaceutical composition of claim 1, wherein the composition is encapsulated, extruded, compressed, pelletized, coated, mixed, granulated, crystallized, lyophilized or molded.
55. The pharmaceutical composition of claim 1, wherein the composition is prepared by spheronization.
56. The pharmaceutical composition of claim 1, wherein the composition is prepared by compression.
57. The pharmaceutical composition of claim 1, wherein the composition is prepared by extrusion.
58. The pharmaceutical composition of claim 1, in the form of a capsule, a tablet, an ovule, a suppository, a wafer, a chewable tablet, a buccal tablet, a sublingual tablet, a quick-dissolve tablet, an effervescent tablet, a granule, a pellet, a bead, a pill, a sachet, a sprinkle, a film, a dry syrup, a reconstitutable solid, a suspension, a lozenge, a troche, an implant, a powder, a triturate, a platelet, or a strip.
59. The pharmaceutical composition of claim 1, wherein the composition is formulated for controlled release.
60. The pharmaceutical composition of claim 59, wherein the controlled release is immediate release, pulsatile release, extended release, delayed release, targeted release, targeted delayed release, or mixtures thereof.
61. The pharmaceutical composition of claim 1, wherein the composition is formulated for oral, nasal, ocular, urethral, buccal, transmucosal, vaginal, topical or rectal delivery.
62. A method of administering an active ingredient to a mammalian patient, the method comprising administering the pharmaceutical composition of claim 1 to the patient.
63. The method of claim 62, wherein the mammal is a human.
64. The pharmaceutical composition of claim 2, wherein the active ingredient is selected from the group consisting of analgesics, anti-inflammatory agents, antihelminthics, anti-arrhythmic agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-diabetics, anti-epileptics, anti-fungal agents, anti-gout agents, anti-hypertensive agents, anti-malarials, anti-migraine agents, anti-muscarinic agents, anti-neoplastic agents, erectile dysfunction improvement agents, immunosuppressants, anti-protozoal agents, anti-thyroid agents, anxioytic agents, sedatives, hypnotics, neuroleptics, \u03b2-blockers, cardiac inotropic agents, corticosteroids, diuretics, anti-parkinsonian agents, gastro-intestinal agents, histamine receptor antagonists, kerarolytics, lipid regulating agents, anti-anginal agents, Cox-2 inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, nutritional agents, opioid analgesics, protease inhibitors, sex hormones, stimulants, muscle relaxants, anti-osteoperosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, nutritional oils, anti-benign prostate hypertrophy agents, essential fatty acids, non-essential fatty acids, and mixtures thereof.
65. The pharmaceutical composition of claim 64, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to facilitate sustained solubilization of the active ingredient upon administration.
66. The pharmaceutical composition of claim 64, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to partially or fully solubilize the active ingredient in the solid carrier.
67. The pharmaceutical composition of claim 64, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to facilitate rapid dispersion of the active ingredient upon administration.
68. The pharmaceutical composition of claim 67, wherein the rapid dispersion comprises micellization andor emulsification.
69. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is PEG-20 sorbitan monooleate.
70. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is selected from the group consisting of PEG-35 caster oil, PEG-40 hydrogenated castor oil, and mixtures thereof.
71. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is tocopheryl PEG-1000 succinate.
72. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is selected from the group consisting of lauryl macrogols-32 glyceride, stearoyl macrogols glyceride and mixtures thereof.
73. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is PEG-8 capryliccapric glyceride.
74. The pharmaceutical composition of claim 64, wherein the hydrophilic surfactant is a poloxamer.
75. The pharmaceutical composition of claim 64, wherein the controlled release is immediate release, extended release, delayed release, pulsatile release, targeted release or mixtures thereof.
76. The pharmaceutical composition of claim 64, wherein the solid carrier is provided with one or more coatings.
77. The pharmaceutical composition of claim 61, wherein the composition is prepared by spheronization, pelletization, coating, balling, extrusion, spray congealing, nanoencapsulation, super critical fluid processes, cryopelletization, mixing, molding, compression, granulation, lyophilization, chilling, agglomeration, congealing, drying, melt extrusion, crystallization, coacervation, and combinations thereof.
78. The pharmaceutical composition of claim 64, wherein the active ingredient is selected from the group consisting of analgesics, anti-bacterial agents, anti-viral agents, anti-inflammatory agents, anti-depressants, anti-diabetics, anti-epileptics, anti-hypertensive agents, anti-migraine agents, immunosupressants, anxiolytic agents, sedatives, hypnotics, neuroleptics, \u03b2-blockers, gastro-intestinal agents, lipid regulating agents, anti-anginal agents, Cox-2 inhibitors, leukotriene inhibitors, macrolides, muscle relaxants, opioid analgesics, protease inhibitors, sex hormones, cognition enhancers, anti-urinary incontinence agents, and mixtures thereof.
79. The pharmaceutical composition of claim 78, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to partially or fully solubilize the active ingredient in the solid carrier.
80. The pharmaceutical composition of claim 78, wherein the effective solubilizing amount of the hydrophilic surfactant is an amount effective to facilitate rapid dispersion of the active ingredient upon administration.
81. The pharmaceutical composition of claim 80, wherein the rapid dispersion comprises micellization andor emulsification.
82. The pharmaceutical composition of claim 2, wherein the active ingredient is selected from the group consisting of acetretin, albendazole, albuterol, aminoglutethimide, amiodarone, amlodipine, amphetamine, amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen, beclomethasone, benezepril, benzonatate, betamethasone, bicalutanide, budesonide, bupropion, busulfan, butenafine, calcifediol, calcipotriene, calcitriol, camptothecin, candesartan, capsaicin, carbamezepine, carotenes, celecoxib, cerivastatin, cetirizine, chlorpheniramine, cholecalciferol, cilostazol, cimetidine, cinnarizine, ciprofloxacin, cisapride, clarithromycin, clemastine, clomiphene, clomipramine, clopidogrel, codeine, coenzyme Q10, cyclobenzaprine, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, dicoumarol, digoxin, dehydroepiandrosterone, dihydroergotamine, dihydotachysterol, dirithromycin, donezepil, efavirenz, eprosartan, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemfibrozil, glibenclamide, glipizide, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irbesartan, irinotecan, isosorbide dinitrate, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, lisinopril, loperamide, loratadine, lovastatin, L-thyroxine, lutein, lycopene, medroxyprogesterone, mifepristone, mefloquine, megestrol acetate, methadone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, minoxidil, mitoxantrone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, nifedipine, nilsolidipine, nilutanide, nitrofurantoin, nizatidine, omeprazole, oprevelkin, oestradiol, oxaprozin, paclitaxel, paracalcitol, paroxetine, pentazocine, pioglitazone, pizofetin, pravastatin, prednisolone, probucol, progesterone, pseudoephedrine, pyridostigmine, rabeprazole, raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sertraline, sibutramine, sildenafil citrate, simvastatin, sirolimus, spironolactone, sumatriptan, tacrine, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, telmisartan, teniposide, terbinafine, terazosin, tetrahydrocannabinol, tiagabine, ticlopidine, tirofibran, tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin, troglitazone, trovafloxacin, ubidecarenone, valsartan, venlafaxine, verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, zolpidem, zopiclone, pharmaceutically acceptable salts, isomers, and derivatives thereof, and mixtures thereof.
83. The pharmaceutical composition of claim 82, wherein the active ingredient is selected from the group consisiting of acetretin, albendazole, albuterol, aminoglutethimide, amiodarone, amlodipine, amphetamine, amphotericin B, atorvastatin, atovaquone, azithromycin, baclofen, benzonatate, bicalutanide, busulfan, butenafine, calcifediol, calcipotriene, calcitriol, camptothecin, capsaicin, carbamezepine, carotenes, celecoxib, cerivastatin, chlorpheniramine, cholecaliferol, cimetidine, cinnarizine, ciprofloxacin, cisapride, cetirizine, clarithromycin, clemastine, clomiphene, codeine, coenzyme Q10, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, digoxin, dehydrepiandrosterone, dihydroergotamine, dihyrotachysterol, dirithromycin, donepezil, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fentanyl, fexofenadine, finasteride, fluconazole, flurbiprofen, fluvastatin, fosphenytoin, frovatriptan, furazolidone, gabapentin, gemifibrozil, glibenclamide, glipizide, glyburide, glimepiride, griseofulvin, halofantrine, ibuprofen, irinotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, lovastatin, L-thryroxine, lutein, lycopene, mifepristone, mefloquine, megestrol acetate, methdone, methoxsalen, metronidazole, miconazole, midazolam, miglitol, mitoxantrone, medroxyprogesterone, montelukast, nabumetone, nalbuphine, naratriptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol, oxaprozin, paclitaxel, paracalcitol, pentazocine, pioglitazone, pizofetin, pravastatin, probucol, progesterone, pseudoephedrine, pyridostigmine, rabeprazole, raloxifine, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sibutramine, sildenafil citrate, simvastatin, siroliumus, spironolactone, sumatriptan, tacrine, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, teniposide, terbinafine, tetrahydrocannabinol, tiagabine, tizanidine, topiramate, topotecan, toremifene, tramadol, tretinoin, troglitazone, trovafloxacin, verteporfin, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, zolpidem, zopiclone, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
84. The pharmaceutical composition of claim 83, wherein the active ingredient is selected from the group consisting of acetretin, albuterol, aminoglutethimide, amiodarone, amlodipine, amprenavir, atorvastatin, atovaquone, baclofen, benzonatate, bicalutanide, busulfan, calcifediol, calcipotriene, calcitrol, camptothecin, capsaicin, carbamezepine, carotenes, celecoxib, chlorpheniramine, cholecaliferol, cimitidine, cinnarizine, cisapride, citrizine, clemastine, coenzyme Q10, cyclosporin, danazol, dantrolene, dexchlorpheniramine, diclofenac, dehydroepiandrosterone, dihydroergotamine, dihyrotachysterol, efavirenz, ergocalciferol, ergotamine, essential fatty acid sources, etodolac, etoposide, famotidine, fenofibrate, fexofenadine, finasteride, fluconazole, flurbiprofen, fosphenytoin, frovatriptan, flurzolidone, glibenclamide, glipizide, glyburide, glymepride, ibuprofen, ironotecan, isotretinoin, itraconazole, ivermectin, ketoconazole, ketorolac, lamotrigine, lansoprazole, leflunomide, loperamide, loratadine, lovastatin, L-thyroxine, lutien, lycopene, medroxyprogesterone, mifepristone, megestrol acetate, methoxsalen, metronidazole, miconazole, miglitol, mitoxantrone, montelukast, nabumetone, naratriptan, nelfinavir, nilutanide, nitrofurantoin, nizatidine, omeprazole, oestradiol, oxaprozin, paclitaxel, paracalcitol, pioglitazone, pizofetin, pranlukast, probucol, progesterone, pseudophedrine, raberprazole, raloxifene, rofecoxib, repaglinide, rifabutine, rifapentine, rimexolone, ritanovir, rizatriptan, rosiglitazone, saquinavir, sildenafil citrate, simvastatin, sirolimus, tramadol, tacrolimus, tamoxifen, tamsulosin, targretin, tazarotene, teniposide, terbenafine, tetrahydrocannabinol, tiagabine, tizanidine, topiramate, topotecan, toremifine, tramadol, tretinoin, troglitazone, trovafloxacin, ubidecarenone, vigabatrin, vitamin A, vitamin D, vitamin E, vitamin K, zafirlukast, zileuton, zolmitriptan, pharmaceutically acceptable salts, isomers and derivative thereof, and mixtures thereof.
85. The pharmaceutical composition of claim 84, wherein the active ingredient is selected from the group consisting of amlodipine, amprenavir, atorvastatin, atovaquone, celecoxib, cisapride, coenzyme Q10, cyclosporin, famotidine, fenofibrate, fexofenadine, finasteride, ibuprofen, itraconazole, lansoprazole, loratadine, lovastatin, megestrol acetate, montelukast, nebumetone, nizatidine, omeprazole, oxaprozin, paclitaxel, paracalcitol, pioglitazone, pranlukast, progesterone, pseudoephedrine, rabeprazole, rapamycin, rofecoxib, repaglinide, rimexolone, ritanovir, rosiglitazone, saquinavir, sildenafil citrate, simvastatin, sirolimus, tramadol, tacrolimus, tamsulosin, teniposide, terbenafine, tetrahydrocannabinol, tiagabine, tizanidine, tramadol, trogliazone, vitamin A, vitamin D, vitamin E, zafirlukast, zileuton, pharmaceutically acceptable salts, isomers and derivatives thereof, and mixtures thereof.
86. The pharmaceutical composition of claim 2, wherein the active ingredient is selected from the group consisting of progesterone, dehydroepiandrosterone, amiodarone, spironolactone and mixtures thereof.
87. The pharmaceutical composition of claim 2, wherein the active ingredient is selected from the group consisting of clopidogrel, pioglitazone, zafirlukast, sertraline, tramadol, and fentanyl.
88. The pharmaceutical composition of claim 2, wherein the active ingredient is selected from the group consisting of tacrolimus, sirolimus, cilostazol, bicalutaminde, simvastatin, and lovastatin.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

What is claimed is:

1. A process comprising solution grafting a hydrocarbon polymer prepared from at least one C2 to C28 polymerizable hydrocarbon, said polymer having a number average molecular weight in the range of from about 5,000 to about 500,000, with an ethylenically unsaturated C3 to C10 carboxylic acid material, using a free radical initiator, in the presence of an aromatic ester oil of the formula
4
wherein R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, COOR7, COOR8, COOR9, COOR10, COOR11, and COOR12, provided that no more than 5 of R1, R2, R3, R4, R5, and R6 are hydrogen, and R7, R8, R9, R10, R11, and R12 are independently selected from the group consisting of alkyl and alkylesters.
2. The process of claim 1, wherein the hydrocarbon polymer is a copolymer of ethylene with a C3 to C28 alpha olefin.
3. The process of claim 2 wherein the copolymer comprises from about 15 to about 90 weight percent ethylene and, correspondingly, from about 85 to about 10 weight percent of the alpha olefin.
4. The process of claim 2 wherein the C3 to C28 alpha olefin is propylene.
5. The process of claim 3 wherein the C3 to C28 alpha olefin is propylene.
6. The process of claim 1, wherein the copolymer is grafted with the unsaturated material by dissolving the copolymer in the aromatic ester and adding the unsaturated material and free radical initiator over about 0.1 to about 12 hours at a temperature of from about 25 C. to about 250 C.
7. The process of claim 6 wherein about 5 to 95% of the copolymer is dissolved in 95 to 5 wt. % of the aromatic ester to form a solution, the amount of the unsaturated material is about 0.05 to 10 wt. % based upon the weight of the solution, and the amount of the initiator is about 0.005 to 10 wt. % based on the weight of the solution.
8. The process of claim 7 further comprising, after the grafting step, the steps of adding about 40 to 500 wt. %, based upon the weight of the solution, of mineral or synthetic lubricating oil and then adding an amine sufficient to neutralize the acid and heating at 100 C. to 250 C. for 0.5 to 10 hours.
9. The process of claim 8, wherein the unsaturated material is maleic anhydride and the amine is N-(4-anilinophenyl)-3-aminobutanamide.
10. The process of claim 7, wherein the unsaturated material is a nitrogen-containing ethylenically unsaturated monomer.
11. The process of claim 10, wherein the nitrogen-containing monomer is selected from the group consisting of vinyl pyridines, vinyl pyrrolidones, vinyl imidazoles, and amine group-contining acrylates and methacrylates.
12. A dispersant-viscosity index improver prepared by a process comprising solution grafting a hydrocarbon polymer prepared from at least one C2 to C28 polymerizable hydrocarbon, said polymer having a number average molecular weight in the range of from about 5,000 to about 500,000, with an ethylenically unsaturated C3 to C10 carboxylic acid material, using a free radical initiator, in the presence of an aromatic ester oil of the formula
5
wherein R1, R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, COOR7, COOR8, COOR9, COOR10, COOR11, and COOR12, provided that no more than 5 of R1, R2, R3, R4, R5, and R6 are hydrogen, and R7, R8, R9, R10, R11, and R12 are independently selected from the group consisting of alkyl and alkylesters.
13. The dispersant-viscosity index improver of claim 12, wherein the hydrocarbon polymer is a copolymer of ethylene with a C3 to C28 alpha olefin.
14. The dispersant-viscosity index improver of claim 13 wherein the copolymer comprises from about 15 to about 90 weight percent ethylene and, correspondingly, from about 85 to about 10 weight percent of the alpha olefin.
15. The dispersant-viscosity index improver of claim 13 wherein the C3 to C28 alpha olefin is propylene.
16. The dispersant-viscosity index improver of claim 14 wherein the C3 to C28 alpha olefin is propylene.
17. The dispersant-viscosity index improver of claim 12, wherein the copolymer is grafted with the unsaturated material by dissolving the copolymer in the aromatic ester and adding the unsaturated material and free radical initiator over about 0.1 to about 12 hours at a temperature of from about 25 C. to about 250 C.
18. The dispersant-viscosity index improver of claim 17 wherein about 5 to 95% of the copolymer is dissolved in 95 to 5 wt. % of the aromatic ester to form a solution, the amount of the unsaturated material is about 0.05 to 10 wt. % based upon the weight of the solution, and the amount of the initiator is about 0.005 to 10 wt. % based on the weight of the solution.
19. The dispersant-viscosity index improver of claim 18 wherein the process further comprises, after the grafting step, the steps of adding about 40 to 500 wt. %, based upon the weight of the solution, of mineral or synthetic lubricating oil and then adding an amine sufficient to neutralize the acid and heating at 100 C. to 250 C. for 0.5 to 1 hours.
20. The dispersant-viscosity index improver of claim 19, wherein the unsaturated material is maleic anhydride and the amine is N-(4-anilinophenyl)-3-aminobutanamide.
21. The dispersant-viscosity index improver of claim 18, wherein the unsaturated material is a nitrogen-containing ethylenically unsaturated monomer.
22. The dispersant-viscosity index improver of claim 21, wherein the nitrogen-containing monomer is selected from the group consisting of vinyl pyridines, vinyl pyrrolidones, vinyl imidazoles, and amine group-contining acrylates and methacrylates.

1. An aqueous resinous binder comprising:
(a) polymeric microparticles obtained by aqueous phase addition polymerization of a monomer component comprising one or more addition polymerizable ethylenically unsaturated monomers in the presence of a polymer dispersed in aqueous medium in which the polymer is selected from a polyester, a polyurethane and an acrylic copolymer including mixtures thereof,
(b) a water-dilutable urethane polyol,
(c) a hydroxyl group-containing material derived from the reaction of an epoxy group-containing material with a phosphorus acid; and
(d) an aqueous dispersion of a reaction product, said reaction product produced by the steps of: reacting trimellitic anhydride and a polyol to form an intermediate reaction product, wherein the molar ratio of trimellitic anhydride to the polyol is from 1:2 to 1:4; and reacting the intermediate reaction product with an anhydride to form said reaction product.
2. The aqueous resinous binder of claim 1 in which the aqueous resinous binder has a resin solids content of from 20 to 60 percent by weight based on total weight of (a)+(b)+(c)+(d).
3. The aqueous resinous binder of claim 1 in which the addition polymerizable ethylenically unsaturated monomers are selected from alkyl esters of acrylic or methacrylic acid, vinylidene halides and hydroxyalkyl esters of acrylic or methacrylic acid including mixtures thereof.
4. The aqueous resinous binder of claim 3 comprising a hydroxyalkyl ester of acrylic acid or methacrylic acid containing from 1 to 4 carbon atoms in the hydroxyalkyl group.
5. The aqueous resinous binder of claim 4 which has a hydroxyl value between 75 and 250.
6. The aqueous resinous binder of claim 1 in which the polyester has an acid number between 10 and 60.
7. The aqueous resinous binder of claim 1 in which the polyester is formed from reacting a polycarboxylic acid with a polyol.
8. The aqueous resinous binder of claim 7 in which a portion of the polycarboxylic acid is selected from maleic acid, fumaric acid and itaconic acid.
9. The aqueous resinous binder of claim 1 in which the urethane polyol is prepared by the reaction of a cyclic carbonate with a polyamine.
10. The aqueous resinous binder of claim 9 in which the cyclic carbonate is a linear or branched aliphatic cyclic carbonate.
11. The aqueous resinous binder of claim 10 in which the cyclic carbonate is a monocarbonate.
12. The aqueous resinous binder of claim 9 in which the polyamine is a polyprimary amine.
13. The aqueous resinous binder of claim 1 in which the hydroxyl functional material (c) is the reaction product of a polyepoxide and a phosphorus acid.
14. The aqueous resinous binder of claim 13 in which the polyepoxide is a polyglycidyl ether of a polyphenol.
15. The aqueous resinous binder of claim 14 in which the phosphorus acid is selected from phosphoric acid and an organic phosphonic acid.
16. The aqueous resinous binder of claim 1 in which the polymeric microparticles (a) are present in the aqueous resinous binder in amounts of 40 to 90 percent by weight based on total weight of resin solids.
17. The aqueous resinous binder of claim 1 in which the water-dilutable urethane polyol is present in the composition in amounts of 5 to 30 percent by weight based on weight of resin solids.
18. The aqueous resinous binder of claim 1 in which component (c) is present in the composition in amounts of 2 to 20 percent by weight based on total weight of resin solids.
19. The aqueous resinous binder of claim 1, which further comprises a curing agent.
20. The aqueous resinous binder of claim 19 in which the curing agent is selected from polyisocyanates including blocked polyisocyanates and aminoplasts.
21. The aqueous resinous binder of claim 19 in which the curing agent is present in amounts of 10 to 30 percent by weight based on total weight of resin solids in the aqueous resinous binder and curing agent.
22. A multilayer composite coating comprising a primer, a basecoat adhered to the primer and a clearcoat adhered to the basecoat, wherein the primer is derived from the aqueous resinous binder of claim 19.
23. The aqueous resinous binder of claim 1, which further comprises pigments.
24. The aqueous resinous binder of claim 23 in which the pigment to resin weight ratio is from 0.2:1.0 to 3.0:1.0.
25. The aqueous resinous binder of claim 1, in which the molar ratio of trimellitic anhydride to the polyol in the reaction product ranges from 1:2.3 to 1:3.3.
26. A multilayer composite coating comprising a primer, a basecoat adhered to the primer and a clearcoat adhered to the basecoat, wherein the primer is derived from the aqueous resinous binder of claim 1.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

We claim:

1. A hydrodynamic seal 103 for sealing between a machine component 109 and a relatively rotatable surface 115 and for serving as a partition between a first fluid 121 and a second fluid 124 and preventing intrusion of the second fluid 124 into the first fluid 121, comprising:
A. an annular seal body 104 having a first seal end 133 and a second seal end 136;
B. an annular static sealing lip 128 defining a sloping static sealing surface 131 for establishing compressed sealing relation with the machine component 109;
C. an annular dynamic sealing lip 127 in generally opposed relation to said static sealing lip 128 for establishing compressed sealing relation with the relatively rotatable surface 115 and defining:
i. a sloping dynamic sealing surface 140 of generally annular form and having variable width and being for establishing compressed sealing relation with the machine component 109;
ii. a hydrodynamic inlet curvature 142 that varies in position relative to said second seal end 136 to form one or more waves for providing hydrodynamic wedging action in response to relative rotation; and
iii. a dynamic exclusionary intersection 139 of substantially abrupt form for facing and preventing intrusion of the second fluid 124.
2. The hydrodynamic seal 103 of claim 1, comprising:
at least one energizer 163 of generally circular form for loading said dynamic sealing lip 127 into compressed sealing relation with the relatively rotatable surface 115.
3. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 being an elastomeric ring.
4. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 being at least one cantilever-type spring.
5. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 being a canted coil spring.
6. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 being a garter coil spring.
7. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 being located between said dynamic sealing lip 127 and said static sealing lip 128.
8. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer 163 defining said static sealing lip 128.
9. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer element having a modulus of elasticity less than the modulus of elasticity of said annular seal body 104.
10. The hydrodynamic seal 103 of claim 2, comprising:
said at least one energizer element having a modulus of elasticity greater than the modulus of elasticity of said annular seal body 104.
11. The hydrodynamic seal 103 of claim 1, comprising:
A. said annular seal body 104 defining a dynamic control surface 145 for facing the relatively rotatable surface 115 and for resisting cross-sectional twisting of said annular seal body 104;
B. said annular seal body 104 defining a static control surface 148 for facing the machine component 109 and for resisting cross-sectional twisting of said annular seal body 104; and
C. said dynamic control surface 145 and said static control surface 148 being in substantially oppositely oriented relation to one another.
12. The hydrodynamic seal 103 of claim 1, comprising:
said dynamic exclusionary intersection 139 being an intersection between said sloping dynamic sealing surface 140 and said second seal end 136.
13. The hydrodynamic seal 103 of claim 1, comprising:
said second seal end 136 projecting outward in a generally convex configuration in the uncompressed condition thereof.
14. The hydrodynamic seal 103 of claim 1, wherein:
A. said annular seal body 104 defining a depth dimension D from said sloping static sealing surface 131 to said sloping dynamic sealing surface 140;
B. said annular seal body 104 defining a length dimension L from said first seal end 133 to said second seal end 136; and
C. the ratio of said length dimension L divided by said depth dimension D being greater than 1.2.
15. The hydrodynamic seal 103 of claim 1, wherein:
A. said annular seal body 104 defining a depth dimension D from said sloping static sealing surface 131 to said sloping dynamic sealing surface 140;
B. said annular seal body 104 defining a length dimension L from said first seal end 133 to said second seal end 136; and
C. the ratio of said length dimension L divided by said depth dimension D being in the range of 1.4 to 1.6.
16. The hydrodynamic seal 103 of claim 1, wherein:
A. said annular seal body 104 defining a depth dimension D from said sloping static sealing surface 131 to said sloping dynamic sealing surface 140; and
B. the magnitude of said depth dimension D varying substantially in time with said position of said hydrodynamic inlet curvature 142.
17. The hydrodynamic seal 103 of claim 1, wherein:
said second seal end 136 defining an annular recess 167 intermediate said dynamic sealing lip 127 and said static sealing lip 128.
18. The hydrodynamic seal 103 of claim 1, wherein:
said first seal end 133 varying in position relative to said second seal end 136 and substantially in time with said position of said hydrodynamic inlet curvature 142.
19. The hydrodynamic seal 103 of claim 1, wherein:
said annular seal body 104 being solid in cross-section.
20. The hydrodynamic seal 103 of claim 1, wherein:
A. said dynamic sealing lip 127 projecting radially inward from said annular seal body 104; and
B. said static sealing lip 128 projecting radially outward from said annular seal body 104.
21. The hydrodynamic seal 103 of claim 1, wherein:
A. said dynamic sealing lip 127 projecting radially outward from said annular seal body 104; and
B. said static sealing lip 128 projecting radially inward from said annular seal body 104.
22. The hydrodynamic seal 103 of claim 1, wherein:
said dynamic sealing lip 127 and said substantially opposite facing static sealing lip 128 both projecting axially from said annular seal body 104.
23. A hydrodynamic seal 103 for sealing between a machine component 109 and a relatively rotatable surface 115 and for serving as a partition between a first fluid 121 and a second fluid 124 and preventing intrusion of the second fluid 124 into the first fluid 121, comprising:
A. an annular seal body 104 having a first seal end 133 and a second seal end 136;
B. an annular dynamic sealing lip 127A in generally opposed relation to said static sealing lip 128 for establishing compressed sealing relation with the relatively rotatable surface 115 and defining:
i. a sloping dynamic sealing surface 140A of generally annular form and having variable width and being for establishing compressed sealing relation with the machine component 109;
ii. a hydrodynamic inlet curvature 142A that varies in position relative to said second seal end 136 to form one or more waves for providing hydrodynamic wedging action in response to relative rotation; and
iii. a dynamic exclusionary intersection 139A of substantially abrupt form for facing and preventing intrusion of the second fluid 124.

C. an annular dynamic sealing lip 127B in generally opposed relation to said dynamic sealing lip 127A for establishing compressed sealing relation with the machine component 109 and defining:
i. a sloping dynamic sealing surface 140B of generally annular form and having variable width and being for establishing compressed sealing relation with the machine component 109;
ii. a hydrodynamic inlet curvature 142B that varies in position relative to said second seal end 136 to form one or more waves for providing hydrodynamic wedging action in response to relative rotation; and
iii. a dynamic exclusionary intersection 139B of substantially abrupt form for facing and preventing intrusion of the second fluid 124.
24. An annular hydrodynamic seal 103 for sealing between a machine component 109 and a relatively rotatable surface 115 and serving as a partition between first and second fluids 121 and 124 and preventing intrusion of the second fluid into the first fluid, comprising:
A. an annular seal body 104 having first and second seal ends;
B. a dynamic sealing lip 127 of generally circular configuration extending from said annular seal body and defining a sloping dynamic sealing surface 140 of variable width and having a hydrodynamic inlet curvature 142 of variable position;
C. a static sealing lip 128 of generally circular configuration extending from said annular seal body and being located in generally opposed relation with said dynamic sealing lip, said static sealing lip defining a sloping static sealing surface; and
D. said sloping dynamic sealing surface 148 and hydrodynamic inlet curvature 142 of said dynamic sealing lip 127 being deformed by compressive engagement with the relatively rotatable surface 115 and defining a hydrodynamic wedging angle and an interfacial contact footprint with respect to the relatively rotatable surface, said interfacial contact footprint having a first footprint edge 157 and a second footprint edge 160, said first footprint edge being of non-circular configuration for hydrodynamically wedging a lubricating film of the first fluid into said interfacial contact footprint responsive to relative rotational velocity, causing the lubricating film to migrate toward said second footprint edge.
25. The annular hydrodynamic seal 103 of claim 24, comprising:
said second footprint edge 160 being of substantially circular configuration and defining a dynamic exclusionary intersection for preventing hydrodynamic wedging action at said second seal end for excluding entry of the second fluid into said interfacial contact footprint.
26. The annular hydrodynamic seal 103 of claim 24, comprising:
said second seal end 136 being of generally convex geometry in the uncompressed state thereof and being deformed to a substantially planar geometry responsive to compression of said annular hydrodynamic seal 103 between said machine component 109 and said relatively rotatable surface 1 5.
27. The annular hydrodynamic seal 103 of claim 24, comprising:
said sloping static sealing surface 131 of said static sealing lip 127 being deformed by compressive engagement with the machine component 109 and defining an interfacial contact footprint with respect thereto.
28. The annular hydrodynamic seal 103 of claim 24, comprising:
said sloping dynamic sealing surface 140 and said sloping static sealing surface 131 each being disposed in angulated relation respectively with said machine component 109 and said relatively rotatable surface 115.
29. The annular hydrodynamic seal 103 of claim 24, comprising:
said sloping dynamic sealing surface 140 and said sloping static sealing surface 131 of said dynamic sealing lip 127 and said static sealing lip 128 each being disposed in angulated relation respectively with the relatively rotatable surface 115 and the machine component 109.
30. An annular hydrodynamic seal 103 for sealing between first and second relatively rotatable members and serving as a partition between first and second fluids and preventing intrusion of the second fluid into the first fluid, comprising:
A. an annular seal body 103 having first and second ends;
B. an annular dynamic sealing lip 127 being integral with said annular seal body and defining at least one annular sloping surface 140 establishing dynamic exclusionary intersection 139 with said second end;
C. said annular sloping surface 140 of said dynamic sealing lip 127 being deformed by compressive engagement with the relatively rotatable surface 115 and defining a generally circular interfacial contact footprint having a first footprint edge 157 and a second footprint edge 160 and varying in width on at least the first footprint edge;
D. said annular sloping surface 140 defining a hydrodynamic wedging angle with respect to the relatively rotatable surface 115 for hydrodynamically wedging a lubricating film of the first fluid into a dynamic sealing interface of the interfacial contact footprint with the relatively rotatable surface 115 in response to relative rotational velocity, causing the lubricant film to migrate within the dynamic sealing interface toward the second footprint edge;
E. an annular static sealing lip 128 extending from said annular seal body and being disposed in oppositely facing relation with said dynamic sealing lip 127, said static sealing lip defining a sloping surface 131 establishing static exclusionary intersection with said second end; and
F. said annular sloping surface 140 of said static sealing lip 127 being deformed by compressive engagement with the machine component 109 and defining a generally circular static interfacial contact footprint with the machine component, the generally circular static interfacial contact footprint having first and second footprint edges.
31. The annular hydrodynamic seal 103 of claim 30, comprising:
said interfacial contact footprint of said dynamic sealing lip 127 having greater interfacial contact pressure at said second footprint edge 160 resulting from deformation of said annular sloping surface 140 as compared with interfacial contact pressure at said first footprint edge 157.
32. The annular hydrodynamic seal 103 of claim 30, comprising:
at least one energizer element 163 loading said annular dynamic and static sloping surfaces against the machine component 109 and the relatively rotatable surface 115 and establishing desired interfacial contact pressure of said annular interfacial contact footprints with the machine component and the relatively rotatable surface.
33. The annular hydrodynamic seal 103 of claim 30, comprising:
said annular seal body 103 defining a dynamic control surface 145 and a static control surface 148 being in substantially opposite facing relation with said dynamic control surface, said dynamic and static control surfaces resisting interference compression induced cross-sectional twisting of said annular seal body.
34. An annular hydrodynamic seal 103 for interference sealing between a machine component 109 and a relatively rotatable surface 1 15 and defining a sealed partition between a lubricant chamber 121 of the machine component and an environment, comprising:
A. an annular seal body 103 having a lubricant end 133 and a environment end 136;
B. a dynamic sealing lip 127 being defined by said annular seal body having a dynamic sealing surface 140 of sloped configuration;
C. said environment end of said annular seal body establishing dynamic exclusionary intersection with said relatively rotatable surface; and
D. upon compression of said seal between said housing and the relatively rotatable surface a portion of said dynamic sealing surface being deformed by and assuming the configuration of said relatively rotatable surface and establishing a dynamic sealing footprint of varying width throughout the circumference thereof; and
E. a static sealing lip 128 being defined by said annular seal body and having a sloped static sealing surface 131 establishing static exclusionary intersection with said environment end surface, said static sealing lip being deformed by interference compression with the housing to define a static sealing footprint establishing a static sealing interface with the machine component.
35. The annular hydrodynamic seal 103 of claim 34, comprising:
an energizing element 163 being located within said environment end of said annular seal body 103 and being located intermediate said environment end surface and between said dynamic sealing lip 127 and said static sealing lip 128 and respectively loading said dynamic and static sealing lips against said relatively rotatable surface and the machine component.
36. The annular hydrodynamic seal 103 of claim 35, comprising:
A. said environment end of said annular seal body 103 defining an annular recess 167; and
B. said energizing element 163 being located within said annular recess.
37. The annular hydrodynamic seal of claim 35, comprising:
said energizing element 163 being an annular spring of generally C-shaped cross-sectional configuration.
38. The annular hydrodynamic seal 103 of claim 35, comprising:
said energizing element 163 being an annular member composed of an elastomer material having a modulus of elasticity less than the modulus of elasticity of said annular seal body.